You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEscitalopram
Accession NumberDB01175  (APRD00683)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEscitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD).
Structure
Thumb
Synonyms
(+)-Citalopram
(S)-Citalopram
Escitalopram Oxalate
Escitalopramum
Esertia
S-(+)-Citalopram
S(+)-Citalopram
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-escitalopramtablet10 mgoralAccord Healthcare Inc2016-06-10Not applicableCanada
Ach-escitalopramtablet20 mgoralAccord Healthcare Inc2016-06-10Not applicableCanada
Act Escitalopramtablet20 mgoralActavis Pharma Company2014-09-10Not applicableCanada
Act Escitalopramtablet5 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Act Escitalopramtablet10 mgoralActavis Pharma Company2014-09-10Not applicableCanada
Act Escitalopram ODTtablet (orally disintegrating)10 mgoralActavis Pharma Company2016-08-17Not applicableCanada
Act Escitalopram ODTtablet (orally disintegrating)20 mgoralActavis Pharma Company2016-08-17Not applicableCanada
Auro-escitalopramtablet5 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-escitalopramtablet15 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-escitalopramtablet10 mgoralAuro Pharma Inc2014-09-10Not applicableCanada
Auro-escitalopramtablet20 mgoralAuro Pharma Inc2014-09-10Not applicableCanada
Cipralex -5mgtablet5 mgoralLundbeck Canada IncNot applicableNot applicableCanada
Cipralex -10mgtablet10 mgoralLundbeck Canada Inc2005-02-14Not applicableCanada
Cipralex -15mgtablet15 mgoralLundbeck Canada IncNot applicableNot applicableCanada
Cipralex -20mgtablet20 mgoralLundbeck Canada Inc2005-02-14Not applicableCanada
Cipralex Meltztablet (orally disintegrating)20 mgoralLundbeck Canada Inc2012-10-04Not applicableCanada
Cipralex Meltztablet (orally disintegrating)10 mgoralLundbeck Canada Inc2012-10-04Not applicableCanada
Escitalopramtablet10 mgoralSivem Pharmaceuticals Ulc2015-01-14Not applicableCanada
Escitalopramtablet10 mgoralSanis Health Inc2014-09-18Not applicableCanada
Escitalopramtablet20 mgoralSivem Pharmaceuticals Ulc2015-01-14Not applicableCanada
Escitalopramtablet20 mgoralSanis Health Inc2014-09-18Not applicableCanada
Escitalopramtablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Escitalopramtablet10 mgoralPro Doc Limitee2014-09-15Not applicableCanada
Escitalopramtablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Escitalopramtablet20 mgoralPro Doc Limitee2014-09-15Not applicableCanada
Escitalopram Oxalatetablet, film coated20 mg/1oralPhysicians Total Care, Inc.2012-10-16Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralActavis Pharma, Inc.2015-04-01Not applicableUs
Escitalopram Oxalatetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2012-02-29Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2012-02-29Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralMylan Institutional Inc.2012-02-29Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralCardinal Health2002-08-14Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralBlenheim Pharmacal, Inc.2016-02-11Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralMylan Pharmaceuticals Inc.2012-02-29Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralMylan Institutional Inc.2012-02-29Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralCardinal Health2002-08-14Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralBlenheim Pharmacal, Inc.2016-02-11Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2012-10-16Not applicableUs
Ipg-escitalopramtablet15 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-escitalopramtablet20 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-escitalopramtablet5 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-escitalopramtablet10 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-escitalopramtablet10 mgoralJamp Pharma Corporation2014-09-11Not applicableCanada
Jamp-escitalopramtablet20 mgoralJamp Pharma Corporation2014-09-11Not applicableCanada
Lexaprotablet, film coated10 mg/1oralUnit Dose Services2002-08-14Not applicableUs
Lexaprotablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2002-08-14Not applicableUs
Lexaprotablet, film coated20 mg/1oralAidarex Pharmaceuticals LLC2002-08-14Not applicableUs
Lexaprotablet20 mg/1oralCardinal Health2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralForest Laboratories, Inc.2002-08-14Not applicableUs
Lexaprotablet20 mg/1oralPhysicians Total Care, Inc.2009-04-15Not applicableUs
Lexaprotablet, film coated10 mg/1oralSTAT Rx USA LLC2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralCardinal Health2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralAidarex Pharmaceuticals LLC2002-08-14Not applicableUs
Lexaprotablet, film coated20 mg/1oralForest Laboratories, Inc.2002-08-14Not applicableUs
Lexaprotablet5 mg/1oralPhysicians Total Care, Inc.2009-11-30Not applicableUs
Lexaprotablet, film coated5 mg/1oralSTAT Rx USA LLC2002-08-14Not applicableUs
Lexaprotablet, film coated20 mg/1oralCardinal Health2002-08-14Not applicableUs
Lexaprotablet, film coated20 mg/1oralbryant ranch prepack2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-14Not applicableUs
Lexaprosolution5 mg/5mLoralForest Laboratories, Inc.2002-11-26Not applicableUs
Lexaprotablet, film coated20 mg/1oralREMEDYREPACK INC.2013-03-182016-03-11Us
Lexaprotablet10 mg/1oralCardinal Health2002-08-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralbryant ranch prepack2002-08-14Not applicableUs
Lexaprotablet, film coated5 mg/1oralForest Laboratories, Inc.2002-08-14Not applicableUs
Lexaprotablet10 mg/1oralPhysicians Total Care, Inc.2005-12-28Not applicableUs
Lexaprotablet, film coated20 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-14Not applicableUs
Lexaprotablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2002-08-14Not applicableUs
Mar-escitalopramtablet15 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-escitalopramtablet10 mgoralMarcan Pharmaceuticals Inc2014-09-10Not applicableCanada
Mar-escitalopramtablet20 mgoralMarcan Pharmaceuticals Inc2014-09-10Not applicableCanada
Mar-escitalopramtablet5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-escitalopramtablet10 mgoralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-escitalopramtablet20 mgoralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-escitalopramtablet15 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-escitalopramtablet10 mgoralMylan Pharmaceuticals Ulc2014-09-10Not applicableCanada
Mylan-escitalopramtablet20 mgoralMylan Pharmaceuticals Ulc2014-09-10Not applicableCanada
Nat-escitalopramtablet10 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-escitalopramtablet20 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
PMS-escitalopramtablet20 mgoralPharmascience Inc2014-09-10Not applicableCanada
PMS-escitalopramtablet5 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-escitalopramtablet15 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-escitalopramtablet10 mgoralPharmascience Inc2014-09-10Not applicableCanada
Priva-escitalopramtablet10 mgoralPharmapar Inc2014-09-10Not applicableCanada
Priva-escitalopramtablet20 mgoralPharmapar Inc2014-09-10Not applicableCanada
Ran-escitalopramtablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.2014-09-10Not applicableCanada
Ran-escitalopramtablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2014-09-10Not applicableCanada
Riva-escitalopramtablet5 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-escitalopramtablet15 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-escitalopramtablet10 mgoralLaboratoire Riva Inc2014-09-25Not applicableCanada
Riva-escitalopramtablet20 mgoralLaboratoire Riva Inc2014-09-25Not applicableCanada
Sandoz Escitalopramtablet20 mgoralSandoz Canada Incorporated2014-09-10Not applicableCanada
Sandoz Escitalopramtablet10 mgoralSandoz Canada Incorporated2014-09-10Not applicableCanada
Teva-escitalopramtablet15 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-escitalopramtablet10 mgoralTeva Canada Limited2014-09-10Not applicableCanada
Teva-escitalopramtablet20 mgoralTeva Canada Limited2014-09-10Not applicableCanada
Teva-escitalopramtablet5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-escitalopramtablet10 mgoralApotex Inc2014-09-10Not applicableCanada
Apo-escitalopramtablet20 mgoralApotex Inc2014-09-10Not applicableCanada
Escitalopramtablet, film coated5 mg/1oralBlue Point Laboratories2014-02-06Not applicableUs
Escitalopramtablet, film coated20 mg/1oralRebel Distributors Corp2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2013-09-052016-04-05Us
Escitalopramtablet, film coated5 mg/1oralHikma Pharmaceutical2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralApotex Corp.2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2012-03-14Not applicableUs
Escitalopramtablet10 mg/1oralTYA Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralDispensing Solutions, Inc.2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-09Not applicableUs
Escitalopramtablet, film coated10 mg/1oralCardinal Health2013-07-01Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2013-02-13Not applicableUs
Escitalopramtablet, film coated10 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralbryant ranch prepack2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralAmerican Health Packaging2013-07-01Not applicableUs
Escitalopramtablet, film coated5 mg/1oralREMEDYREPACK INC.2016-01-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralRebel Distributors Corp2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Escitalopramtablet, film coated10 mg/1oralCitron Pharma LLC2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2014-12-24Not applicableUs
Escitalopramtablet, film coated10 mg/1oralWest Ward Pharmaceuticals Corp2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralAurobindo Pharma Limited2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralAccord Healthcare Inc.2013-01-15Not applicableUs
Escitalopramtablet, film coated20 mg/1oralPreferred Pharmaceuticals, Inc.2014-09-25Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2012-09-11Not applicableUs
Escitalopramtablet, coated20 mg/1oralDIRECT RX2015-01-01Not applicableUs
Escitalopramtablet, film coated20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralBlue Point Laboratories2014-02-06Not applicableUs
Escitalopramtablet5 mg/1oralCamber Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2012-09-11Not applicableUs
Escitalopramtablet20 mg/1oralREMEDYREPACK INC.2014-02-282016-04-05Us
Escitalopramtablet, film coated10 mg/1oralHikma Pharmaceutical2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralSt. Mary's Medical Park Pharmacy2014-02-06Not applicableUs
Escitalopramtablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2012-03-14Not applicableUs
Escitalopramtablet20 mg/1oralTYA Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet20 mg/1oralLegacy Pharmaceutical Packaging2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralNorthwind Pharmaceuticals2014-03-21Not applicableUs
Escitalopramtablet, film coated10 mg/1oralUnit Dose Services2012-03-14Not applicableUs
Escitalopramtablet, film coated5 mg/1oralSTI Pharma LLC2013-09-12Not applicableUs
Escitalopramtablet, film coated20 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralbryant ranch prepack2012-03-14Not applicableUs
Escitalopramtablet10 mg/1oralLupin Pharmaceuticals, Inc.2012-09-10Not applicableUs
Escitalopramtablet, film coated10 mg/1oralAidarex Pharmaceuticals LLC2012-03-14Not applicableUs
Escitalopramtablet, film coated5 mg/1oralSolco Healthcare US, LLC2012-03-15Not applicableUs
Escitalopramtablet, film coated20 mg/1oralSTAT Rx USA LLC2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2013-05-28Not applicableUs
Escitalopramtablet, film coated20 mg/1oralCitron Pharma LLC2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2015-03-09Not applicableUs
Escitalopramtablet, film coated5 mg/1oralWest Ward Pharmaceuticals Corp2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralAurobindo Pharma Limited2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralAccord Healthcare Inc.2013-01-15Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2013-01-18Not applicableUs
Escitalopramtablet, film coated10 mg/1oralProficient Rx LP2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralMajor Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralBlue Point Laboratories2014-02-06Not applicableUs
Escitalopramtablet10 mg/1oralCamber Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralInternational Labs, Inc.2013-09-20Not applicableUs
Escitalopramtablet, film coated20 mg/1oralHikma Pharmaceutical2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2014-11-26Not applicableUs
Escitalopramtablet, film coated20 mg/1oralTeva Pharmaceuticals USA Inc2012-03-14Not applicableUs
Escitalopramtablet10 mg/1oralLegacy Pharmaceutical Packaging2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2013-03-21Not applicableUs
Escitalopramtablet, film coated20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-05-08Not applicableUs
Escitalopramsolution5 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2012-05-03Not applicableUs
Escitalopramtablet, film coated20 mg/1oralUnit Dose Services2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralSTI Pharma LLC2013-09-12Not applicableUs
Escitalopramtablet, film coated5 mg/1oralApotex Corp.2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralbryant ranch prepack2012-03-14Not applicableUs
Escitalopramtablet20 mg/1oralLupin Pharmaceuticals, Inc.2012-09-10Not applicableUs
Escitalopramtablet, film coated10 mg/1oralSolco Healthcare US, LLC2012-03-15Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2013-09-042016-04-05Us
Escitalopramtablet, film coated5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralAurobindo Pharma Limited2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralAccord Healthcare Inc.2013-01-15Not applicableUs
Escitalopramtablet, film coated10 mg/1oralInternational Labs, Inc.2013-09-19Not applicableUs
Escitalopramtablet, film coated5 mg/1oralJubilant Cadista Pharmaceuticals Inc.2014-11-07Not applicableUs
Escitalopramtablet, film coated20 mg/1oralProficient Rx LP2012-03-14Not applicableUs
Escitalopramtablet, film coated20 mg/1oralMajor Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralAmerican Health Packaging2013-07-01Not applicableUs
Escitalopramtablet20 mg/1oralCamber Pharmaceuticals2012-09-11Not applicableUs
Escitalopramtablet, film coated5 mg/1oralAvera Mc Kennan Hospital2015-03-16Not applicableUs
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2013-02-18Not applicableUs
Escitalopramtablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-05-02Not applicableUs
Escitalopramtablet, film coated10 mg/1oralREMEDYREPACK INC.2013-05-02Not applicableUs
Escitalopramtablet, film coated5 mg/1oralCitron Pharma LLC2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralREMEDYREPACK INC.2014-11-28Not applicableUs
Escitalopramtablet, film coated20 mg/1oralWest Ward Pharmaceuticals Corp2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2015-03-26Not applicableUs
Escitalopramtablet, film coated20 mg/1oralMc Kesson Contract Packaging2012-03-14Not applicableUs
Escitalopramtablet, film coated10 mg/1oralUnit Dose Services2012-09-11Not applicableUs
Escitalopramtablet, film coated20 mg/1oralSTI Pharma LLC2013-09-12Not applicableUs
Escitalopramtablet, film coated10 mg/1oralApotex Corp.2012-09-11Not applicableUs
Escitalopramtablet, film coated10 mg/1oralReady Meds2012-03-14Not applicableUs
Escitalopramtablet5 mg/1oralLupin Pharmaceuticals, Inc.2012-09-10Not applicableUs
Escitalopramtablet, film coated20 mg/1oralSolco Healthcare US, LLC2012-03-15Not applicableUs
Escitalopram Oxalatetablet, film coated5 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralDIRECT RX2015-01-01Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/21oralMacleods Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralSilarx Pharmaceuticals, Inc2013-06-12Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralMajor Pharmaceuticals2014-10-15Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralCamber Pharmaceuticals, Inc.2012-06-12Not applicableUs
Escitalopram Oxalatetablet, film coated10 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Escitalopram Oxalatetablet5 mg/1oralTorrent Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/21oralMacleods Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralCardinal Health2014-10-15Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralMajor Pharmaceuticals2014-10-15Not applicableUs
Escitalopram Oxalatetablet, film coated20 mg/1oralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralAmneal Pharmaceuticals of New York, LLC2011-09-03Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralTorrent Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatetablet5 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralAidarex Pharmaceuticals LLC2012-09-11Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralCitron Pharma LLC2012-04-03Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralDIRECT RX2015-01-01Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralLeading Pharma, Llc2015-08-01Not applicableUs
Escitalopram Oxalatesolution5 mg/5mLoralAurobindo Pharma Limited2012-04-03Not applicableUs
Escitalopram Oxalatetablet20 mg/1oralTorrent Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram Oxalatetablet10 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Escitalopram Oxalatetablet, film coated5 mg/1oralMacleods Pharmaceuticals Limited2012-09-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CipralexNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4O4S742ANY
CAS number128196-01-0
WeightAverage: 324.3919
Monoisotopic: 324.163791509
Chemical FormulaC20H21FN2O
InChI KeyInChIKey=WSEQXVZVJXJVFP-FQEVSTJZSA-N
InChI
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
IUPAC Name
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
SMILES
CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Benzonitrile
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
  • 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile (CHEBI:36791 )
Pharmacology
IndicationLabeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.
PharmacodynamicsEscitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase.
Mechanism of actionThe antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Related Articles
AbsorptionThe absolute bioavailability of citalopram is about 80% relative to an intravenous dose.
Volume of distribution
  • 12 L/kg
Protein binding~56%
Metabolism

Mainly hepatic. Escitalopram undergoes N-demethylation to S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT). CYP3A4 and CYP2C19 are the enzymes responsible for this N-demethylation reaction.

Route of eliminationFollowing oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance. Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT).
Half life27-32 hours
Clearance
  • oral cl=600 mL/min [Following oral administrations]
ToxicitySigns of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Escitalopram Action PathwayDrug actionSMP00425
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Sodium-dependent serotonin transporter
Gene symbol: SLC6A4
UniProt: P31645
rs25531 Not AvailableA alleleIncrease risk of side effects (ie. headaches)19272758
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9729
Caco-2 permeable+0.6099
P-glycoprotein substrateSubstrate0.7597
P-glycoprotein inhibitor INon-inhibitor0.6361
P-glycoprotein inhibitor IIInhibitor0.9789
Renal organic cation transporterInhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8401
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.5054
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5223
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.7452
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9054 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7735
hERG inhibition (predictor II)Inhibitor0.8994
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral5 mg
Tabletoral10 mg
Tabletoral15 mg
Tabletoral20 mg
Tablet (orally disintegrating)oral10 mg
Tablet (orally disintegrating)oral20 mg
Tablet, coatedoral20 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Tablet, film coatedoral10 mg/21
Tablet, film coatedoral20 mg/21
Solutionoral5 mg/5mL
Prices
Unit descriptionCostUnit
Lexapro 20 mg tablet3.71USD tablet
Lexapro 10 mg tablet3.55USD tablet
Lexapro 5 mg tablet3.4USD tablet
Lexapro 5 mg/5ml Solution0.72USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1339452 No1997-09-092014-09-09Canada
CA2373757 No2010-01-052020-07-07Canada
US6916941 Yes2003-02-122023-02-12Us
US7420069 Yes2003-02-122023-02-12Us
USRE34712 No1994-09-142011-09-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00588 mg/mLALOGPS
logP3.58ALOGPS
logP3.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.26 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.02 m3·mol-1ChemAxon
Polarizability35.21 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Robert Dancer, “Escitalopram hydrobromide and a method for the preparation thereof.” U.S. Patent US20040167209, issued August 26, 2004.

US20040167209
General References
  1. Moore N, Verdoux H, Fantino B: Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005 May;20(3):131-7. [PubMed:15812262 ]
  2. Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M: A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin. 2006 Jul;22(7):1331-41. [PubMed:16834832 ]
  3. Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004 Sep;65(9):1190-6. [PubMed:15367045 ]
  4. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007 Feb;23(2):401-16. [PubMed:17288694 ]
  5. Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8. [PubMed:15695064 ]
External Links
ATC CodesN06AB10
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (1.09 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Escitalopram.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Escitalopram.
AbirateroneThe metabolism of Escitalopram can be decreased when combined with Abiraterone.
AcarboseEscitalopram may increase the hypoglycemic activities of Acarbose.
AcenocoumarolEscitalopram may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Escitalopram.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Escitalopram.
AcetophenazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Acetophenazine.
Acetylsalicylic acidEscitalopram may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Escitalopram.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Escitalopram.
AlbiglutideEscitalopram may increase the hypoglycemic activities of Albiglutide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Escitalopram.
AlfentanilAlfentanil may increase the serotonergic activities of Escitalopram.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Escitalopram.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Escitalopram.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Escitalopram.
AlogliptinEscitalopram may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Escitalopram.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Escitalopram.
AmantadineAmantadine may increase the QTc-prolonging activities of Escitalopram.
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Escitalopram.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Escitalopram.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Escitalopram.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Escitalopram.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Escitalopram.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Escitalopram.
AmoxapineEscitalopram may increase the serotonergic activities of Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Escitalopram.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Escitalopram.
ApomorphineApomorphine may increase the QTc-prolonging activities of Escitalopram.
AprepitantThe serum concentration of Escitalopram can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Escitalopram.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Escitalopram.
ArmodafinilThe metabolism of Escitalopram can be decreased when combined with Armodafinil.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Escitalopram.
ArtemetherEscitalopram may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Escitalopram.
AsenapineEscitalopram may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe metabolism of Escitalopram can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Escitalopram can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Escitalopram.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Escitalopram.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Escitalopram.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Escitalopram.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Escitalopram.
BendroflumethiazideEscitalopram may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Escitalopram.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Escitalopram.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Escitalopram.
BetaxololThe metabolism of Escitalopram can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Escitalopram can be decreased when it is combined with Bexarotene.
BezitramideBezitramide may increase the serotonergic activities of Escitalopram.
BifeprunoxThe risk or severity of adverse effects can be increased when Escitalopram is combined with Bifeprunox.
BoceprevirThe serum concentration of Escitalopram can be decreased when it is combined with Boceprevir.
BortezomibThe metabolism of Escitalopram can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Escitalopram can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Escitalopram.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Escitalopram.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Escitalopram.
BromocriptineEscitalopram may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Escitalopram.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Escitalopram.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Escitalopram.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Escitalopram.
BuprenorphineBuprenorphine may increase the serotonergic activities of Escitalopram.
BupropionThe metabolism of Escitalopram can be decreased when combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Escitalopram.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Escitalopram.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Escitalopram.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Escitalopram.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Escitalopram.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Escitalopram.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Escitalopram.
ButorphanolButorphanol may increase the serotonergic activities of Escitalopram.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Escitalopram.
CanagliflozinEscitalopram may increase the hypoglycemic activities of Canagliflozin.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Escitalopram.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Escitalopram.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Escitalopram.
CarfentanilCarfentanil may increase the serotonergic activities of Escitalopram.
CariprazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Escitalopram.
CaroxazoneCaroxazone may increase the serotonergic activities of Escitalopram.
CelecoxibThe metabolism of Escitalopram can be decreased when combined with Celecoxib.
CeritinibCeritinib may increase the QTc-prolonging activities of Escitalopram.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Escitalopram.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Escitalopram.
ChloramphenicolThe metabolism of Escitalopram can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Escitalopram.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Escitalopram.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Escitalopram.
ChloroquineChloroquine may increase the QTc-prolonging activities of Escitalopram.
ChlorothiazideEscitalopram may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Escitalopram.
ChlorpromazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Chlorpromazine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Escitalopram.
ChlorpropamideEscitalopram may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Escitalopram.
ChlorthalidoneEscitalopram may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Escitalopram.
CholecalciferolThe metabolism of Escitalopram can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Escitalopram can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Escitalopram can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Escitalopram.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Escitalopram.
CisaprideCisapride may increase the QTc-prolonging activities of Escitalopram.
CitalopramCitalopram may increase the QTc-prolonging activities of Escitalopram.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Escitalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Escitalopram.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Escitalopram.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Escitalopram.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Escitalopram.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Escitalopram.
ClomipramineEscitalopram may increase the serotonergic activities of Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Escitalopram.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Escitalopram.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Escitalopram.
ClotrimazoleThe metabolism of Escitalopram can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Clozapine.
ClozapineClozapine may increase the QTc-prolonging activities of Escitalopram.
CobicistatThe serum concentration of Escitalopram can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Escitalopram.
CodeineCodeine may increase the serotonergic activities of Escitalopram.
ConivaptanThe serum concentration of Escitalopram can be increased when it is combined with Conivaptan.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Escitalopram.
CyamemazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Escitalopram.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Escitalopram.
CyclosporineThe metabolism of Escitalopram can be decreased when combined with Cyclosporine.
CyproheptadineThe therapeutic efficacy of Escitalopram can be decreased when used in combination with Cyproheptadine.
DabrafenibThe serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Escitalopram.
DapagliflozinEscitalopram may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Escitalopram.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Escitalopram.
DapoxetineEscitalopram may increase the serotonergic activities of Dapoxetine.
DarifenacinThe metabolism of Escitalopram can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Escitalopram can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Escitalopram can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Escitalopram can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Escitalopram.
DelavirdineThe metabolism of Escitalopram can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Escitalopram.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Escitalopram.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Escitalopram.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Escitalopram.
DesmopressinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Escitalopram.
DexamethasoneThe serum concentration of Escitalopram can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Escitalopram.
DextromethorphanEscitalopram may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Escitalopram.
DextromoramideDextromoramide may increase the serotonergic activities of Escitalopram.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Escitalopram.
DezocineDezocine may increase the serotonergic activities of Escitalopram.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Escitalopram.
DicoumarolEscitalopram may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Escitalopram.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Escitalopram.
DihydroergotamineThe metabolism of Escitalopram can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Escitalopram.
DihydromorphineDihydromorphine may increase the serotonergic activities of Escitalopram.
DiltiazemThe metabolism of Escitalopram can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Escitalopram.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Escitalopram.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Escitalopram.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Escitalopram.
DofetilideDofetilide may increase the QTc-prolonging activities of Escitalopram.
DolasetronDolasetron may increase the QTc-prolonging activities of Escitalopram.
DomperidoneEscitalopram may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Escitalopram.
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Escitalopram.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Escitalopram.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Escitalopram.
DoxycyclineThe metabolism of Escitalopram can be decreased when combined with Doxycycline.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Escitalopram.
DPDPEDPDPE may increase the serotonergic activities of Escitalopram.
DronedaroneEscitalopram may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Droperidol.
DroperidolDroperidol may increase the QTc-prolonging activities of Escitalopram.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Escitalopram.
DulaglutideEscitalopram may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Escitalopram can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Escitalopram.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Escitalopram.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Escitalopram.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Escitalopram.
EliglustatEscitalopram may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinEscitalopram may increase the hypoglycemic activities of Empagliflozin.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Escitalopram.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Escitalopram.
EnzalutamideThe serum concentration of Escitalopram can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Escitalopram.
ErgonovineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Escitalopram.
EribulinEribulin may increase the QTc-prolonging activities of Escitalopram.
ErythromycinErythromycin may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Escitalopram can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Escitalopram.
EsomeprazoleThe metabolism of Escitalopram can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Escitalopram.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Escitalopram.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Escitalopram.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Escitalopram.
Ethyl biscoumacetateEscitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Escitalopram.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Escitalopram.
EthylmorphineEthylmorphine may increase the serotonergic activities of Escitalopram.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Escitalopram.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Escitalopram.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Escitalopram.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Escitalopram.
EtoperidoneEscitalopram may increase the serotonergic activities of Etoperidone.
EtorphineEtorphine may increase the serotonergic activities of Escitalopram.
EtravirineThe serum concentration of Escitalopram can be decreased when it is combined with Etravirine.
ExenatideEscitalopram may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Escitalopram.
FamotidineFamotidine may increase the QTc-prolonging activities of Escitalopram.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Escitalopram.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Escitalopram.
FenfluramineFenfluramine may increase the serotonergic activities of Escitalopram.
FentanylFentanyl may increase the serotonergic activities of Escitalopram.
FentanylThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Escitalopram.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Escitalopram.
FingolimodFingolimod may increase the QTc-prolonging activities of Escitalopram.
FlecainideFlecainide may increase the QTc-prolonging activities of Escitalopram.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Escitalopram.
FluconazoleThe metabolism of Escitalopram can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Escitalopram.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Escitalopram.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Escitalopram.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Escitalopram.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Escitalopram.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Escitalopram.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Escitalopram.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Escitalopram.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Escitalopram.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Escitalopram.
FluvoxamineEscitalopram may increase the serotonergic activities of Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Escitalopram.
FosamprenavirThe metabolism of Escitalopram can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Escitalopram can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Escitalopram.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Escitalopram.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Escitalopram.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Escitalopram.
FurazolidoneFurazolidone may increase the serotonergic activities of Escitalopram.
Fusidic AcidThe serum concentration of Escitalopram can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Escitalopram.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Escitalopram.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Escitalopram.
GalantamineThe metabolism of Galantamine can be decreased when combined with Escitalopram.
GalantamineGalantamine may increase the QTc-prolonging activities of Escitalopram.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Escitalopram.
GemfibrozilThe metabolism of Escitalopram can be decreased when combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Escitalopram.
GliclazideEscitalopram may increase the hypoglycemic activities of Gliclazide.
GlimepirideEscitalopram may increase the hypoglycemic activities of Glimepiride.
GlipizideEscitalopram may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Escitalopram.
GlyburideEscitalopram may increase the hypoglycemic activities of Glyburide.
GoserelinGoserelin may increase the QTc-prolonging activities of Escitalopram.
GranisetronGranisetron may increase the QTc-prolonging activities of Escitalopram.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Escitalopram.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Escitalopram.
HaloperidolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Haloperidol.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Escitalopram.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Escitalopram.
HeroinHeroin may increase the serotonergic activities of Escitalopram.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Escitalopram.
HistrelinHistrelin may increase the QTc-prolonging activities of Escitalopram.
HydracarbazineHydracarbazine may increase the serotonergic activities of Escitalopram.
HydrochlorothiazideEscitalopram may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Escitalopram.
HydroflumethiazideEscitalopram may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Escitalopram.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Escitalopram.
IbandronateIbandronate may increase the QTc-prolonging activities of Escitalopram.
IbutilideIbutilide may increase the QTc-prolonging activities of Escitalopram.
IdelalisibThe serum concentration of Escitalopram can be increased when it is combined with Idelalisib.
IloperidoneEscitalopram may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Escitalopram can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Escitalopram.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Escitalopram.
IndalpineEscitalopram may increase the serotonergic activities of Indalpine.
IndapamideEscitalopram may increase the hyponatremic activities of Indapamide.
IndapamideIndapamide may increase the QTc-prolonging activities of Escitalopram.
IndinavirThe metabolism of Escitalopram can be decreased when combined with Indinavir.
Insulin AspartEscitalopram may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirEscitalopram may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineEscitalopram may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineEscitalopram may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanEscitalopram may increase the hypoglycemic activities of Insulin Human.
Insulin LisproEscitalopram may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Escitalopram may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Escitalopram.
IproniazidIproniazid may increase the serotonergic activities of Escitalopram.
IsavuconazoniumThe metabolism of Escitalopram can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Escitalopram.
IsocarboxazidThe risk or severity of adverse effects can be increased when Escitalopram is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Escitalopram.
IsoniazidThe metabolism of Escitalopram can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Escitalopram can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Escitalopram can be decreased when combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Escitalopram.
IvacaftorThe serum concentration of Escitalopram can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Escitalopram.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Escitalopram.
KetobemidoneKetobemidone may increase the serotonergic activities of Escitalopram.
KetoconazoleThe metabolism of Escitalopram can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Escitalopram.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Escitalopram.
LanreotideEscitalopram may increase the hypoglycemic activities of Lanreotide.
LapatinibLapatinib may increase the QTc-prolonging activities of Escitalopram.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Escitalopram.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Escitalopram.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Escitalopram.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Escitalopram.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Escitalopram.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Escitalopram.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Escitalopram.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Escitalopram.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Escitalopram.
LevomilnacipranEscitalopram may increase the serotonergic activities of Levomilnacipran.
LevorphanolLevorphanol may increase the serotonergic activities of Escitalopram.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Escitalopram.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Escitalopram.
LinezolidLinezolid may increase the serotonergic activities of Escitalopram.
LinezolidThe risk or severity of adverse effects can be increased when Escitalopram is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Escitalopram.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Escitalopram.
LiraglutideEscitalopram may increase the hypoglycemic activities of Liraglutide.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Escitalopram.
LofentanilLofentanil may increase the serotonergic activities of Escitalopram.
LopinavirEscitalopram may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Escitalopram.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Escitalopram.
LorcaserinThe metabolism of Escitalopram can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Lorcaserin.
LovastatinThe metabolism of Escitalopram can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Escitalopram.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Escitalopram.
Lu AA21004Escitalopram may increase the serotonergic activities of Lu AA21004.
LuliconazoleThe serum concentration of Escitalopram can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Escitalopram can be decreased when it is combined with Lumacaftor.
LumefantrineEscitalopram may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Escitalopram.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Escitalopram.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Escitalopram.
MebanazineMebanazine may increase the serotonergic activities of Escitalopram.
MecaserminEscitalopram may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Escitalopram.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Escitalopram.
MefloquineMefloquine may increase the QTc-prolonging activities of Escitalopram.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Escitalopram.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Escitalopram.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Escitalopram.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Escitalopram.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Escitalopram.
MetforminEscitalopram may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Methadone can be decreased when combined with Escitalopram.
MethadoneMethadone may increase the QTc-prolonging activities of Escitalopram.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Escitalopram.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Escitalopram.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Escitalopram.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Escitalopram.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Escitalopram.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Escitalopram.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Escitalopram.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.
MethyclothiazideEscitalopram may increase the hyponatremic activities of Methyclothiazide.
Methylene blueEscitalopram may increase the serotonergic activities of Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Escitalopram.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Escitalopram.
MetolazoneEscitalopram may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Escitalopram.
MetoprololThe metabolism of Escitalopram can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Escitalopram.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Escitalopram.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Escitalopram.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram.
MifepristoneMifepristone may increase the QTc-prolonging activities of Escitalopram.
MiglitolEscitalopram may increase the hypoglycemic activities of Miglitol.
MilnacipranEscitalopram may increase the serotonergic activities of Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Escitalopram.
MirabegronThe metabolism of Escitalopram can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Escitalopram.
MitotaneThe serum concentration of Escitalopram can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the serotonergic activities of Escitalopram.
MoclobemideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Moclobemide.
ModafinilThe serum concentration of Escitalopram can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Escitalopram.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Escitalopram.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Escitalopram.
MorphineMorphine may increase the serotonergic activities of Escitalopram.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Escitalopram.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Escitalopram.
NafcillinThe serum concentration of Escitalopram can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the serotonergic activities of Escitalopram.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Escitalopram.
NateglinideEscitalopram may increase the hypoglycemic activities of Nateglinide.
NefazodoneThe metabolism of Escitalopram can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Nefazodone.
NelfinavirThe metabolism of Escitalopram can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Escitalopram can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Escitalopram can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Escitalopram.
NicardipineThe metabolism of Escitalopram can be decreased when combined with Nicardipine.
NilotinibEscitalopram may increase the QTc-prolonging activities of Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Escitalopram.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Escitalopram.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Escitalopram.
NormethadoneNormethadone may increase the serotonergic activities of Escitalopram.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Escitalopram.
OctamoxinOctamoxin may increase the serotonergic activities of Escitalopram.
OctreotideEscitalopram may increase the hypoglycemic activities of Octreotide.
OctreotideOctreotide may increase the QTc-prolonging activities of Escitalopram.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Escitalopram.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Escitalopram.
OlaparibThe metabolism of Escitalopram can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Escitalopram.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Escitalopram.
OmeprazoleThe metabolism of Escitalopram can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ondansetron.
OndansetronOndansetron may increase the QTc-prolonging activities of Escitalopram.
OpiumOpium may increase the serotonergic activities of Escitalopram.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Escitalopram.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Escitalopram.
OsimertinibThe serum concentration of Escitalopram can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Escitalopram.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Escitalopram.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Escitalopram.
OxycodoneOxycodone may increase the serotonergic activities of Escitalopram.
OxymorphoneOxymorphone may increase the serotonergic activities of Escitalopram.
OxytocinOxytocin may increase the QTc-prolonging activities of Escitalopram.
PalbociclibThe serum concentration of Escitalopram can be increased when it is combined with Palbociclib.
PaliperidoneEscitalopram may increase the QTc-prolonging activities of Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Escitalopram.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Escitalopram.
PantoprazoleThe metabolism of Escitalopram can be decreased when combined with Pantoprazole.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Escitalopram.
PargylinePargyline may increase the serotonergic activities of Escitalopram.
ParoxetineParoxetine may increase the serotonergic activities of Escitalopram.
PasireotideEscitalopram may increase the hypoglycemic activities of Pasireotide.
PasireotidePasireotide may increase the QTc-prolonging activities of Escitalopram.
PazopanibPazopanib may increase the QTc-prolonging activities of Escitalopram.
Peginterferon alfa-2bThe serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineEscitalopram may increase the hypoglycemic activities of Pentamidine.
PentamidinePentamidine may increase the QTc-prolonging activities of Escitalopram.
PentazocinePentazocine may increase the serotonergic activities of Escitalopram.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Escitalopram.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Escitalopram.
PerflutrenPerflutren may increase the QTc-prolonging activities of Escitalopram.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Escitalopram.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Escitalopram.
PethidinePethidine may increase the serotonergic activities of Escitalopram.
PethidineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pethidine.
PhenelzinePhenelzine may increase the serotonergic activities of Escitalopram.
PhenelzineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Phenelzine.
PhenindioneEscitalopram may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Escitalopram.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Escitalopram.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Escitalopram.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Escitalopram.
PhenprocoumonEscitalopram may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Escitalopram.
PimozideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pimozide.
PimozidePimozide may increase the QTc-prolonging activities of Escitalopram.
PioglitazoneEscitalopram may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Escitalopram.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Escitalopram.
PirlindolePirlindole may increase the serotonergic activities of Escitalopram.
PivhydrazinePivhydrazine may increase the serotonergic activities of Escitalopram.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Escitalopram.
PolythiazideEscitalopram may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.
PosaconazoleThe metabolism of Escitalopram can be decreased when combined with Posaconazole.
PramlintideEscitalopram may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Escitalopram.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Escitalopram.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Escitalopram.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Escitalopram.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Escitalopram.
ProcainamideProcainamide may increase the QTc-prolonging activities of Escitalopram.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Escitalopram.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Escitalopram.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Escitalopram.
PromazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Promazine.
PromazinePromazine may increase the QTc-prolonging activities of Escitalopram.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Escitalopram.
PropafenonePropafenone may increase the QTc-prolonging activities of Escitalopram.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Escitalopram.
PropericiazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Escitalopram.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Escitalopram.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Escitalopram.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Escitalopram.
QuetiapineEscitalopram may increase the QTc-prolonging activities of Quetiapine.
QuinethazoneEscitalopram may increase the hyponatremic activities of Quinethazone.
QuinidineQuinidine may increase the QTc-prolonging activities of Escitalopram.
QuinineQuinine may increase the QTc-prolonging activities of Escitalopram.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Escitalopram.
RanolazineThe metabolism of Escitalopram can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Escitalopram.
RasagilineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Escitalopram.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Escitalopram.
RepaglinideEscitalopram may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Escitalopram.
RifabutinThe metabolism of Escitalopram can be increased when combined with Rifabutin.
RifampicinThe metabolism of Escitalopram can be increased when combined with Rifampicin.
RifapentineThe metabolism of Escitalopram can be increased when combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Escitalopram.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Escitalopram.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Escitalopram.
RitonavirThe metabolism of Escitalopram can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Escitalopram.
RolapitantThe metabolism of Escitalopram can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Escitalopram.
RopiniroleThe metabolism of Escitalopram can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Escitalopram.
RosiglitazoneEscitalopram may increase the hypoglycemic activities of Rosiglitazone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Escitalopram.
SafrazineSafrazine may increase the serotonergic activities of Escitalopram.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Escitalopram.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Escitalopram.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Escitalopram.
SaxagliptinEscitalopram may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram.
SelegilineSelegiline may increase the serotonergic activities of Escitalopram.
SelegilineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Escitalopram.
SertralineEscitalopram may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Escitalopram can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Escitalopram.
SildenafilThe metabolism of Escitalopram can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Escitalopram can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Escitalopram can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Escitalopram.
SitagliptinEscitalopram may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Escitalopram.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Escitalopram.
SorafenibSorafenib may increase the QTc-prolonging activities of Escitalopram.
SotalolSotalol may increase the QTc-prolonging activities of Escitalopram.
St. John's WortThe serum concentration of Escitalopram can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Escitalopram.
SufentanilSufentanil may increase the serotonergic activities of Escitalopram.
SulfadiazineEscitalopram may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleEscitalopram may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Escitalopram.
SulfisoxazoleEscitalopram may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Escitalopram.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Escitalopram.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Escitalopram.
SunitinibEscitalopram may increase the hypoglycemic activities of Sunitinib.
SunitinibSunitinib may increase the QTc-prolonging activities of Escitalopram.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Escitalopram.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Escitalopram.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Escitalopram.
TapentadolTapentadol may increase the serotonergic activities of Escitalopram.
TapentadolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Escitalopram.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Escitalopram.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Escitalopram can be decreased when it is combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Escitalopram.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Escitalopram.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Escitalopram.
TerbinafineThe metabolism of Escitalopram can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Escitalopram.
TetrabenazineEscitalopram may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Escitalopram.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Escitalopram.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Escitalopram.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Escitalopram.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Escitalopram.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Escitalopram.
ThioproperazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Escitalopram.
ThioridazineThioridazine may increase the QTc-prolonging activities of Escitalopram.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Escitalopram.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Escitalopram.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Escitalopram.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Escitalopram.
TiclopidineThe metabolism of Escitalopram can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Escitalopram.
TipranavirThe metabolism of Escitalopram can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Escitalopram.
TocilizumabThe serum concentration of Escitalopram can be decreased when it is combined with Tocilizumab.
TolazamideEscitalopram may increase the hypoglycemic activities of Tolazamide.
TolbutamideEscitalopram may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Escitalopram.
ToloxatoneToloxatone may increase the serotonergic activities of Escitalopram.
TolterodineTolterodine may increase the QTc-prolonging activities of Escitalopram.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Escitalopram.
ToremifeneToremifene may increase the QTc-prolonging activities of Escitalopram.
TramadolEscitalopram may increase the neuroexcitatory activities of Tramadol.
TramadolTramadol may increase the serotonergic activities of Escitalopram.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Escitalopram.
TranylcypromineTranylcypromine may increase the serotonergic activities of Escitalopram.
TranylcypromineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Escitalopram.
TrazodoneEscitalopram may increase the serotonergic activities of Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Escitalopram.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Escitalopram.
TrichlormethiazideEscitalopram may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Escitalopram.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Escitalopram.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Escitalopram.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Escitalopram.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Escitalopram.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Escitalopram.
VandetanibEscitalopram may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Escitalopram.
VemurafenibEscitalopram may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Escitalopram can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Venlafaxine.
VerapamilThe metabolism of Escitalopram can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Escitalopram.
VilanterolVilanterol may increase the QTc-prolonging activities of Escitalopram.
VilazodoneEscitalopram may increase the serotonergic activities of Vilazodone.
VoriconazoleThe metabolism of Escitalopram can be decreased when combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Escitalopram.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Escitalopram.
VortioxetineEscitalopram may increase the serotonergic activities of Vortioxetine.
WarfarinEscitalopram may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Escitalopram.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Escitalopram.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Escitalopram.
ZimelidineEscitalopram may increase the serotonergic activities of Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Escitalopram.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Escitalopram.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Escitalopram.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Escitalopram.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Escitalopram.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Escitalopram.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Escitalopram.
ZuclopenthixolEscitalopram may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Owens MJ, Knight DL, Nemeroff CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001 Sep 1;50(5):345-50. [PubMed:11543737 ]
  2. Owens JM, Knight DL, Nemeroff CB: [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine]. Encephale. 2002 Jul-Aug;28(4):350-5. [PubMed:12232544 ]
  3. Burke WJ: Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. [PubMed:12387707 ]
  4. Waugh J, Goa KL: Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17(5):343-62. [PubMed:12665392 ]
  5. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O: Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003 Jun;167(4):353-62. Epub 2003 Apr 26. [PubMed:12719960 ]
  6. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
  7. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551 ]
  8. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett. 2009 Oct 25;462(3):207-12. doi: 10.1016/j.neulet.2009.07.030. Epub 2009 Jul 16. [PubMed:19616061 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
  2. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
  2. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 03:28